Items Tagged ‘Non-Hodgkin’s Lymphoma’

July 3, 2018

Xalkori® Receives FDA Breakthrough Therapy Designation for Anaplastic Large Cell Lymphoma

By

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Xalkori® (crizotinib) for the treatment of patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK)-positive. The FDA’s Breakthrough Therapy designation is intended to expedite the development and review of a medicine if it is intended […]

View full entry

Tags: News, Non-Hodgkin's Lymphoma


May 31, 2018

FDA Grants Approval of Calquence for the Treatment of Mantle Cell Lymphoma

By

The US Food and Drug Administration (FDA) has granted approval to Calquence (acalabrutinib) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Calquence is a highly-selective, potent Bruton tyrosine kinase (BTK) inhibitor being evaluated for the treatment of multiple B-cell cancers. About mantle cell lymphoma Mantle […]

View full entry

Tags: Acalabrutinib, Bruton tyrosine kinase (BTK) inhibitor, Calquence, Mantle Cell Non-Hodgkin's Lymphoma, MCL, News, Non-Hodgkin's Lymphoma, t mantle cell lymphoma, treatmen


May 23, 2018

FDA Approves Aliqopa for Relapsed Follicular Lymphoma

By

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Aliqopa® (copanlisib), a novel precision cancer medicine that inhibits phosphatidylinositol 3-kinase (PI3K), for the treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies.   Follicular lymphoma is the most common indolent (slow-growing) form of non-Hodgkin’s lymphoma (NHL), […]

View full entry

Tags: Aliqopa, CHRONOS-1 clinical study, copanlisib, follicular non-hodgkin lymphoma, News, Non-Hodgkin's Lymphoma, Precision Cancer Medicine


May 21, 2018

FDA Approves Kymriah for Treatment of Relapsed or Refractory Large B-Cell Lymphoma

By

On May 1, 2018, the United States Food and Drug Administration (FDA) approved Kymriah (tisagenlecleucel), a CD19-directed genetically modified autologous T-cell immunotherapy, for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Approval was based on a clinical trial in adults […]

View full entry

Tags: News, Non-Hodgkin's Lymphoma


January 23, 2018

Keytruda Effective in Patients with Relapsed or Refractory Lymphoma

By

CancerConnect News: Findings from the KEYNOTE-170 clinical trial Presented at the 59th American Society of Hematology (ASH) Annual Meeting suggest that the novel immunotherapy medication keytruda® (pembrolizumab) represents a new treatment option for non-Hodgkin lymphoma. About Keytruda Keytruda is a monoclonal antibody that helps to restore the body’s immune system in fighting cancer. It creates its […]

View full entry

Tags: checkpoint inhibitor, keytruda, Mediastinal Large B-Cell Lymphoma, News, non-hodgkin lymphoma, Non-Hodgkin's Lymphoma, pembrolizumab, Precision Cancer Medicine


January 11, 2018

FDA approves Gazyva for previously untreated follicular lymphoma

By

CancerConnect News: The United States Food and Drug Administration granted regular approval to Gazyva (obinutuzumab) in combination with chemotherapy, followed by Gazyva monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III, or IV follicular lymphoma (FL).1  As previously reported, Gazyva was found […]

View full entry

Tags: News, Non-Hodgkin's Lymphoma


December 13, 2017

Mogamulizumab Superior to Vorinostat in Cutaneous T Cell Lymphoma

By

Results were recently presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta from a international comparative clinical trail evaluating mogamulizumab in patients with previously treated cutaneous T-cell lymphoma (CTCL). Precision cancer medicine utilizes molecular diagnostic testing, including DNA sequencing, to identify cancer-driving abnormalities in a cancer’s genome. Once a […]

View full entry

Tags: American Society of Hematology, ASH, Cutaneous T Cell Lymphoma, Mogamulizumab Vorinostat, News, non-hodgkin lymphoma, Non-Hodgkin's Lymphoma, Precision Cancer Medicine, T-Cell Non-Hodgkin's Lymphoma, targeted therapy


November 15, 2017

Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF)

By

-MF and pcALCL Represent the Most Common Subtypes of Cutaneous T-Cell Lymphoma (CTCL)- -FDA Approval Based on Clinical Trial Results from the Phase 3 ALCANZA and Phase 2 Investigator-Sponsored Studies in CTCL- “Cutaneous T-cell lymphoma is a blood cancer of the skin with no known cure and few new treatment options. It is a disfiguring […]

View full entry

Tags: adcetris, brentuximab, Cutaneous Anaplastic Large Cell Lymphoma, mycosis fungoides, News, Non-Hodgkin's Lymphoma, pcALCL, vedotin


November 6, 2017

FDA approves Calquence Treatment for Treatment of Mantle Cell Lymphoma

By

The U.S. Food and Drug Administration has granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.  Mantle cell lymphoma is a particularly aggressive cancer and new treatments are needed for patients who have not responded to treatment or have relapsed, Mantle […]

View full entry

Tags: Calquence acalabrutinib, Lymphoma, mantle cell lymphoma, Mantle Cell Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma


October 23, 2017

Keytruda® Significantly Prolongs Survival Compared to Chemotherapy First-Line Treatment for Advanced Non-Small Cell Lung Cancer

By

Updated study results presented at the World Congress on Lung Cancer this week continue to demonstrate that treatment of advanced non small cell lung cancer (NSCLC) whose tumors expressed high levels of PD-1 with Keytruda® (pembrolizumab) is superior to standard chemotherapy and significantly improves survival. Lung cancer remains the leading cause of cancer-related deaths worldwide. In […]

View full entry

Tags: immunotherapy, keytruda, News, Non-Hodgkin's Lymphoma, non-small cell lung cancer, opdivo, PD-1, Precision Cancer Medicine


October 18, 2017

FDA Approves Aliqopa for Treatment of Adults with Relapsed Follicular Lymphoma

By

The U.S. Food and Drug Administration today granted accelerated approval to Aliqopa (copanlisib) for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies. “For patients with relapsed follicular lymphoma, the cancer often comes back even after multiple treatments,” said Richard Pazdur, M.D., director of […]

View full entry

Tags: Aliqopa, copanlisib, Follicular Lymphoma, News, Non-Hodgkin's Lymphoma


October 4, 2017

FDA Approves Aliqopa for Relapsed Follicular Lymphoma

By

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Aliqopa® (copanlisib), an intravenously administered pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, for the treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies. Follicular lymphoma is the most common indolent (slow-growing) form of non-Hodgkin’s lymphoma (NHL), which is […]

View full entry

Tags: 2016, advanced, ESMO, keytruda, Lung Cancer, News, Non-Hodgkin's Lymphoma, nsclc, opdivo, PD-1, pembrolizumab, Tecentriq


September 11, 2017

Duvelisib; Promising New Treatment Option for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

By

Results of the Phase 3 DUO study evaluating duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) have been reported and appear very promising.  Although the treatment of CLL/SLL has advanced in recent years, there remains a substantial unmet need with many patients progressing or relapsing following the available therapies […]

View full entry

Tags: Azerra, Chronic Lymphocytic Leukemia, Duvelisib, News, non-hodgkin lymphoma, Non-Hodgkin's Lymphoma, ofatumumab, Small Lymphocytic Lymphoma


June 25, 2013

Routine CT Scans May Not Be Necessary for Many Lymphoma Survivors

By

After treatment for diffuse large B cell lymphoma (DLBCL), only a small minority of patients have a relapse detected through routine surveillance CT scans alone, suggesting that routine scans have limited value for these patients. These results were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO). DLBCL is the […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma


February 10, 2012

Two Different Approaches to Rituxan Both Effective For Follicular Lymphoma

By

Among patients with low-tumor-burden follicular lymphoma who have received initial treatment with Rituxan® (rituximab), waiting until disease progression to take additional Rituxan is as effective as ongoing, maintenance Rituxan. These results were presented at the 53rd Annual meeting of the American Society of Hematology. Follicular lymphoma is an indolent (slow-growing) type of non-Hodgkin’s lymphoma. It […]

View full entry

Tags: Indolent/Low Grade Non-Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma